Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2015-01-15

Clinical Trial Update: A Phase 2 Extension of Study GCS-100-CS-4003 [Phase 2]

View source ↗

Summary

A Phase 2 extension study (GCS-100-CS-4003) for chronic kidney disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GCS-100

Snippet

Sponsor: La Jolla Pharmaceutical Company | Conditions: Chronic Kidney Disease | Phase 2 | Status: WITHDRAWN